Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vishal Parikh

Cardiovascular Disease Rochester, NY Medical Doctor

NPI 1770840969 CMS profile 1389328

1415 Portland Ave Ste 350, Rochester, NY 14621

Open in the dashboard

General payments

$140,668

630 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$13,184 paid to institutions, not to them · program year 2025

Through program year 2025, Vishal Parikh of Rochester, NY is reported in the CMS Open Payments database as having received $140,668 across 630 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $13,184 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $29,935 106
2024 General $30,659 127
2023 General $20,180 112
2022 General $30,057 77
2021 General $25,475 95
2020 General $1,473 59
2019 General $2,889 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vishal Parikh
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Vishal Parikh were reported at $29,935. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Vishal Parikh Cardiovascular Disease median Middle half National median
2019 $2,889 $450 $127–$1,392 $163
2020 $1,473 $242 $77–$751 $114
2021 $25,475 $335 $101–$1,037 $132
2022 $30,057 $395 $121–$1,211 $149
2023 $20,180 $443 $136–$1,283 $160
2024 $30,659 $450 $136–$1,323 $164
2025 $29,935 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $70,373 93 payments
  2. AstraZeneca Pharmaceuticals LP $27,158 72 payments
  3. Lilly USA, LLC $15,812 17 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $15,169 27 payments
  5. Actelion Pharmaceuticals US, Inc. $2,957 157 payments
  6. Abbott Laboratories $2,743 40 payments
  7. BridgeBio Pharma, Inc. $1,994 13 payments
  8. Novartis Pharmaceuticals Corporation $948 57 payments
  9. Merck Sharp & Dohme Corporation $564 24 payments
  10. Amgen Inc. $334 18 payments
  11. Other $2,615 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $118,620 73 payments
  2. Food and Beverage $13,353 521 payments
  3. Travel and Lodging $5,923 28 payments
  4. Consulting Fee $2,250 2 payments
  5. Education $522 6 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE Diabetes $53,224 60 payments
  2. WAINUA $21,445 33 payments
  3. JARDIANCE Diabetes $16,629 32 payments
  4. JARDIANCE Diabetes $15,788 16 payments
  5. Kerendia $14,943 20 payments
  6. FARXIGA $5,681 38 payments
  7. UPTRAVI $2,957 157 payments
  8. Attruby $1,994 13 payments
  9. HeartMate PHP $1,575 13 payments
  10. OPSUMIT $834 11 payments
  11. Other $6,219 271 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,172

Median for Cardiology: 2,533

Drug cost

$2,350,352

Median for Cardiology: $485,213

Branded share of claims

45.7%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 40 $1,440,231
Tyvaso Dpi Treprostinil Brand 14 $330,761
Entresto Sacubitril/Valsartan Brand 184 $224,898
Jardiance Empagliflozin Brand 166 $203,107
Ozempic Semaglutide Brand 35 $48,157
Farxiga Dapagliflozin Propanediol Brand 29 $33,065
Eliquis Apixaban Brand 23 $27,484
Mounjaro Tirzepatide Brand 13 $13,867
Repatha Sureclick Evolocumab Brand 21 $11,140
Midodrine Hcl Generic 53 $7,628

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$49,446

Medicare's payments for the services billed

Medicare patients

158

Average age 72

Services billed

526

67 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 70%
Chronic kidney disease 61%
Atrial fibrillation 57%
Diabetes 54%
Arthritis 50%
Depression 36%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAINUA
  • AstraZeneca Pharmaceuticals LP $18,915
$18,915 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $9,295
  • Lilly USA, LLC $520
$9,815 166 —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $614
$614 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $156
$156 — —
WINREVAIR
  • Merck Sharp & Dohme Corporation $137
$137 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

630 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record